Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )

This secondary analysis of the phase 3 ENSEMBLE trial (NCT04505722) assessed the impact of preexisting humoral immunity to adenovirus 26 (Ad26) on the immunogenicity of Ad26.COV2.S-elicited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific antibody levels in 380 participants in B...

Descripción completa

Detalles Bibliográficos
Autores principales: Le Gars, Mathieu, Sadoff, Jerald, Struyf, Frank, Heerwegh, Dirk, Truyers, Carla, Hendriks, Jenny, Gray, Glenda, Grinsztejn, Beatriz, Goepfert, Paul A, Schuitemaker, Hanneke, Douoguih, Macaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047246/
https://www.ncbi.nlm.nih.gov/pubmed/35429381
http://dx.doi.org/10.1093/infdis/jiac142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047246/
https://www.ncbi.nlm.nih.gov/pubmed/35429381
http://dx.doi.org/10.1093/infdis/jiac142

Ejemplares similares